Histocell present at the 30th edition of EWMA 2020 VIRTUAL


The annual meeting of the European Wound Management Association (EWMA) held between the 18TH and the 19TH of November 2020 has, like every year, various speakers and experts in the area of sciences, more specifically, on wound healing treatment.

For the first time in its history, due to the situation generated by the COVID-19 pandemic and with the aim to safeguarding the health and safety of attendees and team members, it has been decided to develop its program in online modality. The objective of these virtual sessions at EWMA 2020 is to serve as a meeting point for sector professionals for exchange of knowledge and experiences.

The conference starts on November 18 at 10:30h (GTM+ 1) and at 16:30h begins the Webinar organised by Histocell, focussed on oxidative stress. Reoxcare is presented as an innovative treatment in the current market and thanks to its antioxidant properties becomes a new approach to wound healing. Among its actions, it promotes the natural healing of chronic and acute wounds in patients at risk of chronification and favours the activation of wounds in stalled the inflammatory phase, turning pathological inflammation into physiological inflammation.

Histocell biopharmaceutical company’s product applies years of experience studying oxidative stress in regenerative medicine with successful results in wounds from different ethiologies and outstanding effects in diabetic foot ulcers. Moreover, since September 2018 Histocell has its own medical devices manufacturing facility near the city of Bilbao, which provides more control of the whole process.

Since its founding in 1991, the EWMA association has worked to promote the advancement of education and research in epidemiology, pathology, diagnosis, prevention and management of wounds of all native ethiologies. So, in pursuit of reaching a wider audience, the organisation has set up a selection of sessions with simultaneous translations to be followed in French, German, Italian and Spanish.